5 Key Takeaways

• 1

  The FDA has approved secukinumab for adolescents aged 12 and older with moderate to severe hidradenitis suppurativa.

• 2

  Secukinumab is the only interleukin-17A inhibitor approved for pediatric patients with hidradenitis suppurativa.

• 3

  This approval provides a new biologic treatment option for adolescents with limited options for managing HS.

• 4

  Hidradenitis suppurativa is a chronic inflammatory disorder that often begins during adolescence.

• 5

  The approval was supported by adult HS studies and pediatric clinical trial data from other indications.